Barclays & Lazard Capital Upgrade Human Genome Sciences (HGSI)
More News related to HGSI
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN(TM)
- Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors
- Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
- Human Genome (HGSI) Receives U.S. FDA Response Letter for Anthrax Treatment Raxibacumab
Barclays upgrades Human Genome Sciences (Nasdaq: HGSI) from Equalweight to Overweight
Lazard Capital also upgrades Human Genome Sciences from Hold to Buy.
To see more analyst ratings on HGSI Click Here.
Human Genome Sciences (HGS) is a commercially focused biopharmaceutical company.
Related Categories
UpgradesStocks Mentioned
-0.85Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
